Britannia Life Sciences Inc (TSE:BLAB)
:BLAB
Want to see TSE:BLAB full AI Analyst Report?
BLAB Stock Chart & Stats
C$0.08
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.08
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.14
Previous CloseN/A
Volume35.00K
Average Volume (3M)73.07K
Market Cap
C$14.60M
Enterprise ValueC$13.03M
Total Cash (Recent Filing)C$15.89M
Total Debt (Recent Filing)C$248.56K
Price to Earnings (P/E)0.3
Beta-1.37
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)1.93
Price to Sales (P/S)32.95
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Improved Balance SheetA materially de-levered balance sheet with debt-to-equity near 0.01 provides durable financial resilience. Low leverage lowers refinancing risk, preserves optionality to invest in capabilities or absorb losses, and gives the firm time to convert capital strength into consistent operating performance.
End-to-end Product Development ServicesA full-lifecycle service model across health, beauty and food creates durable competitive advantages: cross-selling, higher client switching costs, and multiple revenue touchpoints. Structural demand for regulatory, formulation and testing services supports repeat business and relevance across economic cycles.
Revenue Model Built On Long-term Contracts And AnalyticsWinning long-term contracts and offering analytics fosters recurring fee streams and deeper client relationships. These durable ties reduce churn, enable predictable project pipelines, and allow margin expansion via bundled services if the firm sustains delivery quality and retains regulatory expertise.
Bears Say
Material Cash Burn And Negative Free Cash FlowPersistent negative operating and free cash flow raises lasting funding risk: it can force dilutive equity or higher-cost debt raises, restrict investment in sales and R&D, and prolong the timeline to profitable scale. Continued cash burn undermines the balance sheet advantage over time.
Volatile, Weakening Revenue TrendsHighly variable revenue and a recent steep drop impair forecasting, reduce operating leverage, and complicate capacity planning. Structural instability in top-line growth limits management's ability to convert contracts into reliable profits and raises the risk of sustained margin pressure.
Overall Weak Financial Quality Despite Balance Sheet GainsThe firm's low financial-quality score reflects persistent profitability and cash-generation weaknesses that can persist despite low leverage. Inconsistent returns on equity and episodic profits indicate structural execution challenges that may prevent durable margin recovery and stable scaling.
Britannia Life Sciences Inc News
BLAB FAQ
What was Britannia Life Sciences Inc’s price range in the past 12 months?
Britannia Life Sciences Inc lowest stock price was C$0.05 and its highest was C$0.14 in the past 12 months.
What is Britannia Life Sciences Inc’s market cap?
Britannia Life Sciences Inc’s market cap is C$14.60M.
When is Britannia Life Sciences Inc’s upcoming earnings report date?
Britannia Life Sciences Inc’s upcoming earnings report date is Aug 04, 2026 which is in 99 days.
How were Britannia Life Sciences Inc’s earnings last quarter?
Britannia Life Sciences Inc released its earnings results on Mar 02, 2026. The company reported C$0.075 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.075.
Is Britannia Life Sciences Inc overvalued?
According to Wall Street analysts Britannia Life Sciences Inc’s price is currently Overvalued.
Does Britannia Life Sciences Inc pay dividends?
Britannia Life Sciences Inc does not currently pay dividends.
What is Britannia Life Sciences Inc’s EPS estimate?
Britannia Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Britannia Life Sciences Inc have?
Britannia Life Sciences Inc has 162,254,330 shares outstanding.
What happened to Britannia Life Sciences Inc’s price movement after its last earnings report?
Britannia Life Sciences Inc reported an EPS of C$0.075 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Britannia Life Sciences Inc?
Currently, no hedge funds are holding shares in TSE:BLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Britannia Life Sciences Inc
Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.
Technical Analysis
Hemostemix
―
Innovotech
―
Sirona Biochem
―
Glow LifeTech
―
Telescope Innovations Corp
―
Options Prices
Currently, No data available
---